[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336391-105":59,"doc-detail-336391-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","merkel-cell-carcinoma-integrating-epidemiology-immunology-and-therapeutic-updates","Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates","","Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer driven by Merkel cell polyomavirus integration or ultraviolet (UV) mutagenesis, both producing high immunogenicity via viral protein expression or neoantigens. Despite this immune visibility, MCC shows highly aggressive clinical behavior, and its natural course remains uncertain due to rarity and limited epidemiologic registries. Conventional chemotherapy historically gave brief median response durations (~3 months), whereas since 2017 multiple PD-1/PD-L1 inhibitors (avelumab, pembrolizumab, nivolumab, retifanlimab) demonstrate efficacy for disseminated MCC. Evidence generation is difficult in rare cancers, yet immunotherapy yields comparable response rates with more durable outcomes; adjuvant nivolumab improves on observation in the adjuvant setting.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/merkel-cell-carcinoma-integrating-epidemiology-immunology-and-therapeutic-updates/336391/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/merkel-cell-carcinoma-integrating-epidemiology-immunology-and-therapeutic-updates/336391.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What causes Merkel cell carcinoma according to the abstract?","Question",{"text":112,"@type":113},"MCC arises either from integration of the Merkel cell polyomavirus or from ultraviolet (UV) mutagenesis. Both routes lead to high immunogenicity through viral proteins or neoantigens.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is understanding MCC’s natural course challenging?",{"text":117,"@type":113},"Because MCC is extremely rare and detailed epidemiologic registries with clinical data are lacking. This limits certainty about the spontaneous disease course.",{"name":119,"@type":110,"acceptedAnswer":120},"How has treatment for advanced MCC changed since 2017?",{"text":121,"@type":113},"Historically, conventional cytotoxic chemotherapy produced a median response duration of about 3 months. Since 2017, PD-1/PD-L1 immune checkpoint inhibitors (avelumab, pembrolizumab, nivolumab, retifanlimab) have shown efficacy in prospective clinical trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336391,1790473539,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","American Journal of Clinical Dermatology (2024) 25:541–557  \n[https://doi.org/10.1007/s40257-024-00858-z](https://doi.org/10.1007/s40257-024-00858-z)  \nMerkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates  \nJürgen C. Becker1,2,3 · Andreas Stang4,5 · David Schrama6 · Selma Ugurel2  \nAccepted: 21 March 2024 / Published online: 22 April 2024 © The Author(s) 2024  \nAbstract  \nMerkel cell carcinoma (MCC) is a rare skin cancer characterized by neuroendocrine differentiation. Its carcinogenesis is based either on the integration of the Merkel cell polyomavirus or on ultraviolet (UV) mutagenesis, both of which lead to high immunogenicity either through the expression of viral proteins or neoantigens. Despite this immunogenicity resulting from viral or UV-associated carcinogenesis, it exhibits highly aggressive behavior. However, owing to the rarity of MCC and the lack of epidemiologic registries with detailed clinical data, there is some uncertainty regarding the spontaneous course of the disease. Historically, advanced MCC patients were treated with conventional cytotoxic chemotherapy yielding a median response duration of only 3 months. Starting in 2017, four programmed cell death protein 1 (PD-1)/programmed cell deathligand 1 (PD-L1) immune checkpoint inhibitors—avelumab, pembrolizumab, nivolumab (utilized in both neoadjuvant and adjuvant settings), and retifanlimab—have demonstrated efficacy in treating patients with disseminated MCC on the basis of prospective clinical trials. However, generating clinical evidence for rare cancers, such as MCC, is challenging owing to difficulties in conducting large-scale trials, resulting in small sample sizes and therefore lacking statistical power. Thus, to comprehensively understand the available clinical evidence on various immunotherapy approaches for MCC, we also delve into the epidemiology and immune biology of this cancer. Nevertheless, while randomized studies directly comparing immune checkpoint inhibitors and chemotherapy in MCC are lacking, immunotherapy shows response rates comparable to those previously reported with chemotherapy but with more enduring responses. Notably, adjuvant nivolumab has proven superiority to the standard-of-care therapy (observation) in the adjuvant setting.  \n* Jürgen C. Becker [j.becker@dkfz.de](j.becker@dkfz.de)  \n1 Department of Translational Skin Cancer Research (TSCR), German Cancer Consortium (DKTK), partner site Essen, University Duisburg-Essen, Universitätsstrasse 1, 45141 Essen, Germany  \n2 Department of Dermatology, University Medicine Essen, Essen, Germany  \n3 German Cancer Research Center (DKFZ), Heidelberg, Germany  \n4 Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany  \n5 Cancer Registry of North Rhine-Westphalia, Bochum, Germany  \n6 Department of Dermatology, University Hospital Würzburg, Würzburg, Germany  \nKey Points  \nMerkel cell carcinoma is an uncommon type of skin cancer that behaves aggressively. It is caused by either a virus or exposure to sunlight, making it highly likely to trigger the body’s immune response.  \nUntil recently, standard chemotherapy for advanced Merkel cell carcinoma provided only short-lived benefits, typically lasting around 3 months. However, since 2017, new drugs called PD-1/PD-L1 inhibitors, such asavelumab, pembrolizumab, nivolumab, and retifanlimab, have shown great promise in clinical trials.  \nBecause Merkel cell carcinoma induces strong immune responses, it often develops ways to avoid being attacked by the body’s immune system. This unfortunately also leads to primary and secondary resistance to PD-1/ PD-L1 gene inhibitors. Researchers are now testing combinations of different treatments to overcome this problem.  \n1 Epidemiology  \nExamining the epidemiology of Merkel cell carcinoma (MCC) poses challenges owing to its extreme rarity. Valuable population-based data regarding incidence and survival can only be reliably obt","cbCaimxEXCrJZ5z9","https://ap.wps.com/l/cbCaimxEXCrJZ5z9","pdf",1185369,17,"English","# Abstract\n# Key Points\n# 1 Epidemiology","[{\"question\":\"What causes Merkel cell carcinoma according to the abstract?\",\"answer\":\"MCC arises either from integration of the Merkel cell polyomavirus or from ultraviolet (UV) mutagenesis. Both routes lead to high immunogenicity through viral proteins or neoantigens.\"},{\"question\":\"Why is understanding MCC’s natural course challenging?\",\"answer\":\"Because MCC is extremely rare and detailed epidemiologic registries with clinical data are lacking. This limits certainty about the spontaneous disease course.\"},{\"question\":\"How has treatment for advanced MCC changed since 2017?\",\"answer\":\"Historically, conventional cytotoxic chemotherapy produced a median response duration of about 3 months. Since 2017, PD-1/PD-L1 immune checkpoint inhibitors (avelumab, pembrolizumab, nivolumab, retifanlimab) have shown efficacy in prospective clinical trials.\"}]","Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates | PDF",1790014827,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78cd80780cdc0527b3bb5ee6471f3aaa.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09211f831626821de10993f3d25b1ed1.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/022d2d38937acfb526d37507ad62bf81.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fc79f0eb37ff610ffd081f4fa467e07.webp",980,1301]